What is Bellevue Life Sciences Acquisition Financial Strength?
Bellevue Life Sciences Acquisition has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Bellevue Life Sciences Acquisition Corp shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Bellevue Life Sciences Acquisition has no long-term debt (1).
As of today, Bellevue Life Sciences Acquisition's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of Bellevue Life Sciences Acquisition's Financial Strength
For the Shell Companies subindustry, Bellevue Life Sciences Acquisition's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bellevue Life Sciences Acquisition's Financial Strength Distribution in the Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Bellevue Life Sciences Acquisition's Financial Strength distribution charts can be found below:
* The bar in red indicates where Bellevue Life Sciences Acquisition's Financial Strength falls into.
Bellevue Life Sciences Acquisition Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Bellevue Life Sciences Acquisition's Interest Expense for the
months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-0.86 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.
Bellevue Life Sciences Acquisition's Interest Coverage for the quarter that ended in Dec. 2023 is
| Bellevue Life Sciences Acquisition had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Bellevue Life Sciences Acquisition's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Bellevue Life Sciences Acquisition has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) Business Description
Traded in Other Exchanges
N/A
Address
10900 NE 4th Street, Suite 2300, Bellevue, WA, USA, 98004
Bellevue Life Sciences Acquisition Corp is a blank check company.
Executives
| David Jin Yoo |
officer: Chief Financial Officer |
(135-270) 7TH FLOOR, SOFTFORUM B/D., 545-7 DOGOKDONG, GANGNAM, SEOUL M5 135-170 |
| Kuk Hyoun Hwang |
director, 10 percent owner, officer: Chief Executive Officer |
10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004 |
| Bellevue Global Life Science Investors Llc |
10 percent owner |
10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004 |
| Steven Reed |
other: Director Nominee |
2843-122 PL. N.E., BELLEVUE WA 98005 |
| In Chul Chung |
other: Director Nominee |
10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004 |
| Hosun Euh |
other: Director Nominee |
10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004 |
| Jin Whan Park |
other: Director Nominee |
10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004 |
| Jun Chul Whang |
director |
10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004 |
| Rad Roberts |
other: Director Nominee |
10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004 |
Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BLAC has been successfully added to your